Cynomolgus studies with lead TRACTrs have demonstrated safety proof-of-concept to support IND-enabling development activities. Our lead TRACTr product candidates are designed to target PSMA, EGFR, and TROP2. Each of these tumor targets are clinically validated and implicated in solid tumors with high prevalence. We are also applying our proprietary technology to develop a costimulatory bispecific product candidate against programmed death-ligand 1 (PD-L1) and CD28 designed to further enhance the anti-tumor activity of T cells, which we believe has the potential to be used as a single-agent or in combination with our current TRACTr pipeline.

ProgramTargetsInitial IndicationsLead DiscoveryLead OptimizationIND EnablingPhase 1Phase 2/3
PSMA-TRACTrPSMAxCD3 mCRPC

 

EGFR-TRACTrEGFRxCD3 CRC, HNC

 

TROP2-TRACTrTROP2xCD3 TNBC, UC, NSCLC

 

Costim bispecificPD-L1xCD28 Solid Tumors

 

DrugStage
PSMA-TRACTr
PSMAxCD3
IND Enabling
EGFR-TRACTr
EGFRxCD3
Lead Optimization
TROP2-TRACTr
TROP2xCD3
Lead Optimization
Costim bispecific
PD-L1xCD28
Lead Optimization